

ORIGINAL ARTICLE

Triple Therapy for Cystic Fibrosis *Phe508del*-Gating and -Residual Function Genotypes

P.J. Barry, M.A. Mall, A. Álvarez, C. Colombo, K.M. de Winter-de Groot, I. Fajac, K.A. McBennett, E.F. McKone, B.W. Ramsey, S. Sutharsan, J.L. Taylor-Cousar, E. Tullis, N. Ahluwalia, L.S. Jun, S.M. Moskowitz, V. Prieto-Centurion, S. Tian, D. Waltz, F. Xuan, Y. Zhang, S.M. Rowe, and D. Polineni, for the VX18-445-104 Study Group*

ABSTRACT

BACKGROUND

Elexacaftor–tezacaftor–ivacaftor is a small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen shown to be efficacious in patients with at least one *Phe508del* allele, which indicates that this combination can modulate a single *Phe508del* allele. In patients whose other CFTR allele contains a gating or residual function mutation that is already effectively treated with previous CFTR modulators (ivacaftor or tezacaftor–ivacaftor), the potential for additional benefit from restoring *Phe508del* CFTR protein function is unclear.

METHODS

We conducted a phase 3, double-blind, randomized, active-controlled trial involving patients 12 years of age or older with cystic fibrosis and *Phe508del*-gating or *Phe508del*-residual function genotypes. After a 4-week run-in period with ivacaftor or tezacaftor–ivacaftor, patients were randomly assigned to receive elexacaftor–tezacaftor–ivacaftor or active control for 8 weeks. The primary end point was the absolute change in the percentage of predicted forced expiratory volume in 1 second (FEV₁) from baseline through week 8 in the elexacaftor–tezacaftor–ivacaftor group.

RESULTS

After the run-in period, 132 patients received elexacaftor–tezacaftor–ivacaftor and 126 received active control. Elexacaftor–tezacaftor–ivacaftor resulted in a percentage of predicted FEV₁ that was higher by 3.7 percentage points (95% confidence interval [CI], 2.8 to 4.6) relative to baseline and higher by 3.5 percentage points (95% CI, 2.2 to 4.7) relative to active control and a sweat chloride concentration that was lower by 22.3 mmol per liter (95% CI, 20.2 to 24.5) relative to baseline and lower by 23.1 mmol per liter (95% CI, 20.1 to 26.1) relative to active control (P<0.001 for all comparisons). The change from baseline in the Cystic Fibrosis Questionnaire–Revised respiratory domain score (range, 0 to 100, with higher scores indicating better quality of life) with elexacaftor–tezacaftor–ivacaftor was 10.3 points (95% CI, 8.0 to 12.7) and with active control was 1.6 points (95% CI, –0.8 to 4.1). The incidence of adverse events was similar in the two groups; adverse events led to treatment discontinuation in one patient (elevated aminotransferase level) in the elexacaftor–tezacaftor–ivacaftor group and in two patients (anxiety or depression and pulmonary exacerbation) in the active control group.

CONCLUSIONS

Elexacaftor–tezacaftor–ivacaftor was efficacious and safe in patients with *Phe508del*-gating or *Phe508del*-residual function genotypes and conferred additional benefit relative to previous CFTR modulators. (Funded by Vertex Pharmaceuticals; VX18-445-104 ClinicalTrials.gov number, NCT04058353.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Polineni at the Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd., MS 3007, Kansas City, KS 66160, or at dpolineni@kumc.edu.

*The members of the VX18-445-104 Study Group are listed in the Supplementary Appendix, available at NEJM.org.

Drs. Barry and Mall and Drs. Rowe and Polineni contributed equally to this article.

N Engl J Med 2021;385:815-25.

DOI: 10.1056/NEJMoa2100665

Copyright © 2021 Massachusetts Medical Society.

CME
at NEJM.org

CYSTIC FIBROSIS IS A LIFE-SHORTENING autosomal recessive disease that affects more than 80,000 people worldwide.^{1,3} In cystic fibrosis, deficiencies in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial anion channel, manifest as a complex multiorgan disease, including progressive respiratory impairment, exocrine pancreatic insufficiency, hepatobiliary disease, and abnormal sweat composition.^{1,3} Measurement of sweat chloride concentration is a key diagnostic test for cystic fibrosis, and the concentration is used as an indicator of systemic CFTR function in clinical trials.⁴

Cystic fibrosis results from biallelic mutations in the *CFTR* gene.¹ More than 1000 pathogenic *CFTR* mutations have been identified.^{5,6} Processing and trafficking mutations (e.g., *Phe508del*, the most common *CFTR* mutation) reduce the quantity of CFTR on the cell surface,^{1,6,7} and channel-gating defects (e.g., *Gly551Asp* and other *CFTR* gating mutations) limit anion transport. *CFTR* mutations that result in lesser impairment of CFTR protein activity, collectively defined as residual function mutations, have also been identified.^{1,8} Most patients with gating or residual function *CFTR* mutations are heterozygous for the *Phe508del* mutation.⁶

Elucidation of the molecular consequences of *CFTR* mutations has supported the development of small-molecule modulators capable of restoring CFTR protein function.⁹⁻¹⁵ Ivacaftor, a CFTR potentiator, augments gating of mutant CFTR proteins.⁹ In patients with gating mutations, ivacaftor improves lung function, nutritional status, and quality of life and decreases pulmonary exacerbations.^{10,16} Ivacaftor monotherapy is also efficacious and safe in patients with residual function mutations.⁸

Tezacaftor is a CFTR corrector that ameliorates the defects in CFTR protein processing and cell-surface trafficking intrinsic to *Phe508del*.¹¹ Because *Phe508del* CFTR proteins also possess gating defects,⁹ modulation requires both correction and potentiation. In patients heterozygous for *Phe508del* and specific residual function mutations, the combination of tezacaftor and ivacaftor improved lung function and sweat chloride concentrations as compared with ivacaftor alone.⁸

The recently developed CFTR corrector elexacaftor has a mechanism of action that is complementary to that of tezacaftor.¹³ Pivotal studies

showed that elexacaftor–tezacaftor–ivacaftor was efficacious and safe in patients with two *Phe508del* alleles and also in those with one *Phe508del* allele and an allele that makes no CFTR protein, which indicates that the presence of a single *Phe508del* allele is sufficient to confer responsiveness.^{13,14} These findings suggest that elexacaftor–tezacaftor–ivacaftor would provide additional clinical benefit in patients with *Phe508del*–gating and *Phe508del*–residual function genotypes by enhancing CFTR activity from the *Phe508del* allele. Here, we report results of a trial (VX18-445-104) designed to evaluate the magnitude of benefit of elexacaftor–tezacaftor–ivacaftor as compared with ivacaftor and tezacaftor–ivacaftor in patients 12 years of age or older with these genotypes.

METHODS

PATIENTS, TRIAL DESIGN, AND OVERSIGHT

This phase 3, multicenter, double-blind, parallel-group, randomized, active-controlled trial of elexacaftor–tezacaftor–ivacaftor enrolled patients 12 years of age or older with cystic fibrosis and *Phe508del*–gating or *Phe508del*–residual function genotypes. Complete inclusion and exclusion criteria as well as additional details on trial design, dosing, and statistical analysis are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org; qualifying mutations are listed in Table S1.

To establish a reliable on-treatment baseline, patients entered a 4-week run-in period to receive either ivacaftor at a dose of 150 mg every 12 hours (ivacaftor comparator cohort; *Phe508del*–gating genotypes, including *Phe508del*–*Arg117His*) or tezacaftor at a dose of 100 mg once daily combined with ivacaftor (tezacaftor–ivacaftor comparator cohort; *Phe508del*–residual function genotypes) (Fig. S1). These genotype-defined comparator cohorts were based on approved indications for CFTR modulators in each country where the trial was conducted.

After the run-in period, patients who entered the 8-week treatment period were randomly assigned in a 1:1 ratio to receive either elexacaftor–tezacaftor–ivacaftor (elexacaftor, 200 mg once daily) or the regimen they received during the run-in period (ivacaftor or tezacaftor–ivacaftor). Stratification of randomization was determined during the run-in period on the basis of comparator cohort (ivacaftor vs. tezacaftor–ivacaftor),

percentage of predicted forced expiratory volume in 1 second (FEV₁; <70 vs. ≥70), and sweat chloride concentration (<30 mmol per liter vs. ≥30 mmol per liter).

The trial was designed by Vertex Pharmaceuticals in collaboration with the authors. Each patient or the patient's legal guardian provided written informed consent, with assent obtained when age appropriate. Safety was monitored by an independent data monitoring committee. During the trial, the coronavirus disease 2019 pandemic led to the implementation of a global protocol addendum enabling patients to remain in the trial with in-home assessments and trial-drug provision. Data collection and analysis were performed by Vertex Pharmaceuticals in collaboration with the authors and the VX18-445-104 Study Group. The first two authors and last two authors wrote the first manuscript draft. All the authors had full access to the trial data after the final database lock, critically reviewed the manuscript, and approved it for submission. The investigators vouch for the accuracy and completeness of data generated at their respective sites, and the investigators and Vertex Pharmaceuticals vouch for the fidelity of the trial to the protocol, available at NEJM.org. Confidentiality agreements were in place between the sponsor and each investigative site during the trial.

END POINTS

The primary end point was the absolute change in the percentage of predicted FEV₁ from baseline through week 8 in the elexacaftor–tezacaftor–ivacaftor group. Key secondary end points, in hierarchical order, were the absolute change in sweat chloride concentration from baseline through week 8 in the elexacaftor–tezacaftor–ivacaftor group, the absolute change in the percentage of predicted FEV₁ from baseline through week 8 for elexacaftor–tezacaftor–ivacaftor as compared with active control (ivacaftor or tezacaftor–ivacaftor), and the absolute change in sweat chloride concentration from baseline through week 8 for elexacaftor–tezacaftor–ivacaftor as compared with active control. Other secondary end points were the absolute change in the score on the respiratory domain of the Cystic Fibrosis Questionnaire–Revised (CFQ-R; range, 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms) from baseline through week 8 in the

elexacaftor–tezacaftor–ivacaftor group and for elexacaftor–tezacaftor–ivacaftor as compared with active control, as well as safety and the side-effect profile. The percentages of patients who reached sweat chloride concentrations below 60 mmol per liter and below 30 mmol per liter were assessed in a post hoc analysis.

STATISTICAL ANALYSIS

Efficacy analyses included all the patients who underwent randomization and received at least one dose during the treatment period. The absolute change from baseline in the percentage of predicted FEV₁ through week 8 was analyzed with the use of a mixed-effects model for repeated measures. The model included treatment group, visit, and treatment-group-by-visit interaction as fixed effects as well as continuous baseline percentage of predicted FEV₁, continuous baseline sweat chloride concentration, and comparator cohort (ivacaftor vs. tezacaftor–ivacaftor) as covariates, with an unstructured covariance used for within-patient errors. The primary result that was obtained from the model was the estimated within-group change from baseline in the percentage of predicted FEV₁ through week 8 for elexacaftor–tezacaftor–ivacaftor. A similar mixed-effects model for repeated measures was applied to each of the key secondary end points. A hierarchical testing procedure was used to control the overall type I error rate at an alpha level of 0.05 for the primary and key secondary end points, the latter of which were prioritized in the testing hierarchy as a within-group analysis of sweat chloride concentration through week 8, a between-group analysis of the percentage of predicted FEV₁ through week 8, and a between-group analysis of sweat chloride concentration through week 8. For a hypothesis test to be considered statistically significant, the P value for that test and all the preceding tests in the hierarchy had to be below 0.05. Within- and between-group analyses of the other secondary end point of the absolute change in the CFQ-R respiratory domain score through week 8 were performed in a manner similar to the analyses of the primary and key secondary end points.

Subgroup analyses according to comparator cohort (ivacaftor [*Phe508del*–gating genotypes] vs. tezacaftor–ivacaftor [*Phe508del*–residual function genotypes]) were performed in a manner

Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*

Characteristic	Elxacaftor–Tezacaftor– Ivacaftor (N=132)	Active Control: Ivacaftor or Tezacaftor–Ivacaftor (N=126)
Sex — no. (%)		
Male	65 (49.2)	65 (51.6)
Female	67 (50.8)	61 (48.4)
Age		
Mean — yr	37.7±14.7	37.6±14.3
Distribution — no. (%) †		
12 to <18 yr	15 (11.4)	9 (7.1)
≥18 yr	117 (88.6)	117 (92.9)
Hispanic or Latino ethnic group — no. (%) ‡		
Hispanic or Latino	5 (3.8)	4 (3.2)
Not Hispanic or Latino	117 (88.6)	114 (90.5)
Not collected per local regulations	10 (7.6)	8 (6.3)
Race or ethnic group — no. (%) ‡§		
White	122 (92.4)	111 (88.1)
Black	0	2 (1.6)
American Indian or Alaska Native	0	1 (0.8)
Other	1 (0.8)	4 (3.2)
Not collected per local regulations	9 (6.8)	9 (7.1)
Geographic region — no. (%)		
North America	49 (37.1)	48 (38.1)
Europe	70 (53.0)	64 (50.8)
Australia	13 (9.8)	14 (11.1)
Genotype — no. (%) ¶		
<i>Phe508del</i> –gating	50 (37.9)	45 (35.7)
<i>Phe508del</i> –residual function	82 (62.1)	81 (64.3)
Percentage of predicted FEV ₁		
Mean	67.1±15.7	68.1±16.4
Distribution — no. (%)		
<40%	2 (1.5)	2 (1.6)
40 to <70%	70 (53.0)	63 (50.0)
70 to ≤90%	53 (40.2)	52 (41.3)
>90%	7 (5.3)	9 (7.1)
Sweat chloride concentration — mmol/liter	59.5±27.0	56.4±25.5
CFQ-R respiratory domain score	76.5±16.6	77.3±15.8
Body-mass index**	24.07±4.72	24.05±4.71

* Plus–minus values are means ±SD. Shown are the demographic and clinical characteristics of the full analysis set, which was defined as all randomly assigned patients who received at least one dose of trial drug in the treatment period. Baseline was defined as the most recent nonmissing measurement before the first dose of trial drug in the treatment period (after the 4-week run-in period). Percentages may not total 100 because of rounding. FEV₁ denotes forced expiratory volume in 1 second.

† Age distribution was calculated on the basis of age at the time of screening.

‡ Ethnic group and race were reported by the patient.

§ There were no patients of Asian race or Native Hawaiian or other Pacific Islander ethnic group. If a patient was reported to have multiple races or ethnic groups, then the patient was counted for each race or ethnic group reported.

¶ Patients with *Phe508del*–gating genotypes who were assigned to the active control group received ivacaftor, and patients with *Phe508del*–residual function genotypes who were assigned to the active control group received tezacaftor–ivacaftor.

|| Scores on the respiratory domain of the Cystic Fibrosis Questionnaire–Revised (CFQ-R) range from 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms.

** The body-mass index is the weight in kilograms divided by the square of the height in meters.

similar to the main analyses, including those for absolute changes in the percentage of predicted FEV₁, in sweat chloride concentration, and in the CFQ-R respiratory domain score. Except for those involving the primary end point, these subgroup analyses were post hoc.

RESULTS

POPULATION

The trial was conducted at 96 sites in North America, Europe, and Australia, from August 28, 2019, to June 12, 2020. Overall, 271 patients entered the 4-week run-in period. After the run-in period, 258 patients (95 with *Phe508del*-gating genotypes and 163 with *Phe508del*-residual function genotypes) were randomly assigned to either the elexacaftor-tezacaftor-ivacaftor group (132 patients) or the active control group (126 patients) and received at least one dose of trial medication. Additional details on patient recruitment are provided in Figure S2. Treatment groups were well matched at baseline (Table 1 and Table S2). Demographic and clinical characteristics at baseline according to comparator cohort and treatment assignment (Table S3) and individual mutations on the second *CFTR* allele according to treatment assignment (Table S4) are provided in the Supplementary Appendix.

EFFICACY

Overall

The mean absolute change in the percentage of predicted FEV₁ from baseline (measured at the end of the run-in period) through week 8 with elexacaftor-tezacaftor-ivacaftor treatment (the primary end point) was 3.7 percentage points (95% confidence interval [CI], 2.8 to 4.6; $P < 0.001$) (Table 2 and Fig. 1A). In contrast, the mean absolute change with active control (ivacaftor or tezacaftor-ivacaftor) was 0.2 percentage points (95% CI, -0.7 to 1.1), reflecting a between-group difference of 3.5 percentage points (95% CI, 2.2 to 4.7; $P < 0.001$). The mean absolute change in sweat chloride concentration from baseline through week 8 with elexacaftor-tezacaftor-ivacaftor was -22.3 mmol per liter (95% CI, -24.5 to -20.2; $P < 0.001$), as compared with a mean absolute change with active control of 0.7 mmol per liter (95% CI, -1.4 to 2.8), reflecting a between-group difference of -23.1 mmol per liter (95% CI, -26.1 to -20.1; $P < 0.001$) (Table 2 and Fig. 1B). The

mean absolute change in the CFQ-R respiratory domain score from baseline through week 8 with elexacaftor-tezacaftor-ivacaftor was 10.3 points (95% CI, 8.0 to 12.7) and with active control was 1.6 points (95% CI, -0.8 to 4.1), reflecting a between-group difference of 8.7 points (95% CI, 5.3 to 12.1) (Table 2 and Fig. 1C).

Subgroup Analyses

The results of a prespecified subgroup analysis of the primary end point (within-group absolute change from baseline in the percentage of predicted FEV₁) according to age at screening (<18 years vs. ≥18 years), sex, comparator cohort (*Phe508del*-gating vs. *Phe508del*-residual function genotypes), percentage of predicted FEV₁ at baseline (<70 vs. ≥70), and geographic region (North America vs. Europe and Australia) were consistent with the results of the primary analysis (Fig. S3A). The same held for the results of a post hoc subgroup analysis of the between-group difference in the change from baseline in the percentage of predicted FEV₁ (Fig. S3B).

Additional post hoc analyses were performed to assess the role of genotype in treatment response. For patients with *Phe508del*-gating genotypes, including *Phe508del-Arg117His*, the mean absolute change in the percentage of predicted FEV₁ from baseline through week 8 with elexacaftor-tezacaftor-ivacaftor was 5.8 percentage points (95% CI, 4.2 to 7.4) and with ivacaftor control was 0.1 percentage points (95% CI, -1.6 to 1.7), for a difference of 5.8 percentage points (95% CI, 3.5 to 8.0); the mean absolute change in sweat chloride concentration with elexacaftor-tezacaftor-ivacaftor was -21.8 mmol per liter (95% CI, -25.7 to -17.8) and with ivacaftor was -1.8 mmol per liter (95% CI, -5.7 to 2.2), for a difference of -20.0 mmol per liter (95% CI, -25.4 to -14.6); and the mean absolute change in the CFQ-R respiratory domain score with elexacaftor-tezacaftor-ivacaftor was 10.2 points (95% CI, 6.6 to 13.8) and with ivacaftor was 1.3 points (95% CI, -2.5 to 5.2), for a difference of 8.9 points (95% CI, 3.8 to 14.0) (Table 3). The results of a post hoc analysis of data from patients with the *Phe508del-Arg117His* genotype were consistent with the results for the overall *Phe508del*-gating cohort (Table S5).

For patients with *Phe508del*-residual function genotypes, the mean absolute change in the percentage of predicted FEV₁ from baseline through

End Point	Elexacaftor–Tezacaftor– Ivacaftor (N = 132)	Active Control: Ivacaftor or Tezacaftor–Ivacaftor (N = 126)
Percentage of predicted FEV ₁		
Value at baseline	67.1±15.7	68.1±16.4
Absolute change from baseline through wk 8		
Sample size†	115	114
Least-squares mean change (95% CI)	3.7 (2.8 to 4.6)‡§	0.2 (–0.7 to 1.1)
Between-group difference (95% CI)	3.5 (2.2 to 4.7)¶	
Sweat chloride concentration		
Value at baseline — mmol/liter	59.5±27.0	56.4±25.5
Absolute change from baseline through wk 8		
Sample size†	120	119
Least-squares mean change (95% CI) — mmol/liter	–22.3 (–24.5 to –20.2)§¶	0.7 (–1.4 to 2.8)
Between-group difference (95% CI) — mmol/liter	–23.1 (–26.1 to –20.1)¶	
CFQ-R respiratory domain score**		
Value at baseline	76.5±16.6	77.3±15.8
Absolute change from baseline through wk 8		
Sample size††	130	126
Least-squares mean change (95% CI)	10.3 (8.0 to 12.7)	1.6 (–0.8 to 4.1)
Between-group difference (95% CI)	8.7 (5.3 to 12.1)	

* Plus–minus values are means ±SD. Baseline, considered to be the end of the run-in period, was defined as the most recent nonmissing measurement before the first dose of trial drug in the treatment period.

† The sample size is the number of patients through week 8 with in-clinic data that could be evaluated.

‡ The primary end point was the absolute change in the percentage of predicted FEV₁ from baseline through week 8 in the elexacaftor–tezacaftor–ivacaftor group.

§ P<0.001 for the within-group change from baseline.

¶ The key secondary end points, in hierarchical order, were the absolute change in sweat chloride concentration from baseline through week 8 in the elexacaftor–tezacaftor–ivacaftor group, the absolute change in the percentage of predicted FEV₁ from baseline through week 8 for elexacaftor–tezacaftor–ivacaftor as compared with active control, and the absolute change in sweat chloride concentration from baseline through week 8 for elexacaftor–tezacaftor–ivacaftor as compared with active control.

|| P<0.001 for the between-group difference in the change from baseline.

** Pooled CFQ-R data were obtained both in the clinic and in the home and were based on both the “Children Ages 12 and 13” and “Adolescents and Adults” versions. The minimal clinically important difference for the CFQ-R respiratory domain score is 4 points.

†† The sample size is the number of patients through week 8 with in-clinic or in-home data that could be evaluated.

week 8 with elexacaftor–tezacaftor–ivacaftor was 2.5 percentage points (95% CI, 1.4 to 3.5) and with tezacaftor–ivacaftor control was 0.5 percentage points (95% CI, –0.5 to 1.5), for a difference of 2.0 percentage points (95% CI, 0.5 to 3.4); the mean absolute change in sweat chloride concentration with elexacaftor–tezacaftor–ivacaftor was –23.1 mmol per liter (95% CI, –25.6 to –20.6) and with tezacaftor–ivacaftor was 1.7 mmol per liter (95% CI, –0.9 to 4.3), for a difference of

–24.8 mmol per liter (95% CI, –28.4 to –21.2); and the mean absolute change in the CFQ-R respiratory domain score with elexacaftor–tezacaftor–ivacaftor was 10.4 points (95% CI, 7.2 to 13.7) and with tezacaftor–ivacaftor was 1.9 points (95% CI, –1.4 to 5.1), for a difference of 8.5 points (95% CI, 4.0 to 13.1) (Table 3).

After 8 weeks of treatment with elexacaftor–tezacaftor–ivacaftor, the mean (±SD) sweat chloride concentrations were 32.7±23.5 mmol per

Figure 1. Efficacy End Points.

Panel A shows the absolute change from baseline at each visit in the percentage of predicted forced expiratory volume in 1 second (FEV₁) on the basis of a mixed-effects model for repeated measures. Panel B shows the absolute change from baseline at each visit in the sweat chloride concentration on the basis of a mixed-effects model for repeated measures. Panel C shows the absolute change from baseline at each visit in the score on the respiratory domain of the Cystic Fibrosis Questionnaire–Revised (CFQ-R) on the basis of a mixed-effects model for repeated measures. Respiratory domain scores are normalized to a 100-point range, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms; the minimal clinically important difference (MCID) is 4 points and is indicated in the plot by the straight gray line. In Panels A through C, data are least-squares means, and the I bars indicate standard errors; the dashed line at 0 corresponds to no change from baseline. The sample size shown under each x axis is the number of patients at that time point with data that could be evaluated. ELX–TEZ–IVA denotes elxacaftor–tezacaftor–ivacaftor, IVA ivacaftor, and TEZ–IVA tezacaftor–ivacaftor.

liter for patients with *Phe508del*–gating genotypes and 39.9±19.3 mmol per liter for those with *Phe508del*–residual function genotypes, as compared with 52.0±21.9 mmol per liter with ivacaftor and 63.4±27.3 mmol per liter with tezacaftor–ivacaftor for patients in those active control groups. An analysis of individual sweat chloride concentrations through week 8 for patients who received elxacaftor–tezacaftor–ivacaftor showed that 83.3% had concentrations below 60 mmol per liter and 50.0% had concentrations below 30 mmol per liter; for patients who received active control, the corresponding percentages were 55.5% and 17.6% (Fig. S4 and Table S6). For patients with *Phe508del*–gating genotypes, 65% who received elxacaftor–tezacaftor–ivacaftor were below 30 mmol per liter through week 8, as compared with 16% of those who received ivacaftor. For patients with *Phe508del*–residual function genotypes, 42% who received elxacaftor–tezacaftor–ivacaftor were below 30 mmol per liter through week 8, as compared with 19% of those who received tezacaftor–ivacaftor.

SAFETY

Overall, 66.7% of the patients in the elxacaftor–tezacaftor–ivacaftor group and 65.9% of those in the active control group (ivacaftor or tezacaftor–




Table 3. Subgroup Analysis of Efficacy Results According to Comparator Cohort.*

Variable	<i>Phe508del</i> –Gating Genotypes		<i>Phe508del</i> –Residual Function Genotypes	
	Elexacaftor–Tezacaftor–Ivacaftor (N=50)	Active Control: Ivacaftor (N=45)	Elexacaftor–Tezacaftor–Ivacaftor (N=82)	Active Control: Tezacaftor–Ivacaftor (N=81)
Percentage of predicted FEV ₁				
Value at baseline	66.0±14.8	68.1±16.6	67.8±16.3	68.1±16.4
Absolute change from baseline through wk 8 (95% CI)	5.8 (4.2 to 7.4)	0.1 (–1.6 to 1.7)	2.5 (1.4 to 3.5)	0.5 (–0.5 to 1.5)
Between-group difference (95% CI)	5.8 (3.5 to 8.0)		2.0 (0.5 to 3.4)	
Sweat chloride concentration — mmol/liter				
Value at baseline	50.9±23.3	47.6±19.1	64.7±27.9	61.4±27.3
Absolute change from baseline through wk 8 (95% CI)	–21.8 (–25.7 to –17.8)	–1.8 (–5.7 to 2.2)	–23.1 (–25.6 to –20.6)	1.7 (–0.9 to 4.3)
Between-group difference (95% CI)	–20.0 (–25.4 to –14.6)		–24.8 (–28.4 to –21.2)	
CFQ-R respiratory domain score†				
Value at baseline	76.3±16.4	75.8±17.6	76.7±16.9	78.1±14.7
Absolute change from baseline through wk 8 (95% CI)	10.2 (6.6 to 13.8)	1.3 (–2.5 to 5.2)	10.4 (7.2 to 13.7)	1.9 (–1.4 to 5.1)
Between-group difference (95% CI)	8.9 (3.8 to 14.0)		8.5 (4.0 to 13.1)	

* Plus–minus values are means ±SD. Baseline was defined as the most recent nonmissing measurement before the first dose of trial drug in the treatment period. Absolute changes from baseline are least-squares means. A similar mixed-effects model for repeated measures as for the primary analysis was applied to each subgroup category, with treatment group, visit, and treatment-group-by-visit interaction as fixed effects and continuous baseline percentage of predicted FEV₁ and continuous baseline sweat chloride concentration as covariates. Model-based estimates for a given category are shown here provided that the analysis converged in that category. All subgroup analyses, except those involving the primary end point of the absolute change in the percentage of predicted FEV₁ from baseline through week 8 with elexacaftor–tezacaftor–ivacaftor, were post hoc.

† The minimal clinically important difference for the CFQ-R respiratory domain score is 4 points.

ivacaftor) had one or more adverse events, which for most patients were mild or moderate in severity and resolved during the trial (Table 4). Serious adverse events were reported in 5 patients (3.8%) in the elexacaftor–tezacaftor–ivacaftor group and 11 patients (8.7%) in the active control group, with the difference attributable to a higher incidence of pulmonary exacerbation in the active control group. One patient in the elexacaftor–tezacaftor–ivacaftor group discontinued treatment owing to an adverse event (elevated aminotransferase level), and 2 patients in the active control group discontinued treatment owing to an adverse event (anxiety or depression in 1 patient and pulmonary exacerbation in 1 patient).

On the basis of previous experience with elexacaftor–tezacaftor–ivacaftor, including the phase 3 trials,^{14,17} data regarding aminotransferase levels, rash, creatine kinase level, and blood pressure were reviewed. Elevated levels of alanine aminotransferase or aspartate aminotransferase that were greater than three times, greater than five times, and greater than eight times the upper limit of the normal range occurred in 4 of 125 patients for whom data were available (3.2%), 1 patient (0.8%), and 1 patient (0.8%), respectively, in the elexacaftor–tezacaftor–ivacaftor group and in 2 of 123 patients (1.6%), 1 patient (0.8%), and no patients, respectively, in the active control group (Table S7). Eight patients (6.1%) in the elexacaftor–tezacaftor–ivacaftor group and

Table 4. Adverse Events.*

Adverse Event	Elexacaftor–Tezacaftor– Ivacaftor (N=132)	Active Control: Ivacaftor or Tezacaftor–Ivacaftor (N=126)
	<i>number of patients (percent)</i>	
Any adverse event	88 (66.7)	83 (65.9)
Adverse event according to maximum severity		
Mild	58 (43.9)	50 (39.7)
Moderate	25 (18.9)	29 (23.0)
Severe	5 (3.8)	4 (3.2)
Life-threatening	0	0
Serious adverse event	5 (3.8)	11 (8.7)
Infective pulmonary exacerbation of cystic fibrosis†	2 (1.5)	7 (5.6)
Adverse event leading to treatment discontinuation	1 (0.8)	2 (1.6)
Adverse event leading to death	0	0
Most common adverse events‡		
Headache	11 (8.3)	19 (15.1)
Alanine aminotransferase increased	8 (6.1)	0
Aspartate aminotransferase increased	8 (6.1)	0
Abdominal pain	7 (5.3)	2 (1.6)
Sputum increased	6 (4.5)	8 (6.3)
Diarrhea	5 (3.8)	8 (6.3)
Cough	3 (2.3)	18 (14.3)
Infective pulmonary exacerbation of cystic fibrosis	3 (2.3)	13 (10.3)
Nausea	2 (1.5)	9 (7.1)
Any adverse event involving rash§	4 (3.0)	5 (4.0)
Any adverse event involving elevated aminotransferase level¶	8 (6.1)	1 (0.8)

* A patient with multiple events within a category was counted only once in that category.

† Infective pulmonary exacerbation of cystic fibrosis was the only serious adverse event that occurred in two or more patients in either treatment group.

‡ Shown are adverse events that occurred in at least 5% of the patients in either group. Adverse events are listed according to the preferred term in the *Medical Dictionary for Regulatory Activities* (MedDRA), version 23.0.

§ Adverse events involving rash included the MedDRA terms rash, rash erythematous, rash maculopapular, rash papular, skin exfoliation, and urticaria.

¶ Shown are adverse events that included the MedDRA terms alanine aminotransferase increased, aspartate aminotransferase increased, and liver function test increased.

|| This adverse event was reported as the MedDRA term liver function test increased.

1 patient (0.8%) in the active control group had adverse events involving elevated aminotransferase levels (Table 4). No patient had a serious adverse event involving elevated aminotransferase levels. Rash was observed in 4 patients (3.0%) in the elexacaftor–tezacaftor–ivacaftor group and in 5 patients (4.0%) in the active control group (Table S8). All cases of rash were mild or moderate in severity. Increased blood creatine kinase levels were reported in 2 patients (1.5%) in the elexacaftor–tezacaftor–ivacaftor group and

in no patients in the active control group. Baseline mean systolic and diastolic blood pressures increased by 3.0 mm Hg and 2.5 mm Hg, respectively, in the elexacaftor–tezacaftor–ivacaftor group and by 0.5 mm Hg and 0.3 mm Hg, respectively, in the active control group at week 8 (Table S9). There were no adverse events involving hypertension in the elexacaftor–tezacaftor–ivacaftor group or the active control group. There were no notable safety findings in other clinical or laboratory assessments.

DISCUSSION

Here, we report results of an 8-week trial of elxacaftor–tezacaftor–ivacaftor in patients with cystic fibrosis and either *Phe508del*–gating or *Phe508del*–residual function genotypes. Elxacaftor–tezacaftor–ivacaftor treatment improved lung function and sweat chloride concentration relative to an active control (ivacaftor or tezacaftor–ivacaftor). Most patients had adverse events that were mild or moderate in severity and that were consistent with those observed in previous studies.^{14,17} These results confirm that by enhancing activity from the *Phe508del* allele, elxacaftor–tezacaftor–ivacaftor can provide additional benefit to patients with a single *Phe508del* allele plus a gating or residual function allele that is responsive to previous CFTR modulator regimens.

For patients with *CFTR* gating mutations, the current benchmark for effective treatment is ivacaftor monotherapy, which has been shown to improve the percentage of predicted FEV₁ by 10.6 percentage points in patients with the *Gly551Asp* gating mutation relative to placebo.¹⁰ In previous studies, tezacaftor–ivacaftor improved the percentage of predicted FEV₁ by 6.8 percentage points in patients with *Phe508del*–residual function genotypes relative to placebo.⁸ Despite the clinical heterogeneity of these genotype groups, elxacaftor–tezacaftor–ivacaftor treatment resulted in additional increases in the percentage of predicted FEV₁ as compared with either ivacaftor or tezacaftor–ivacaftor treatment; this is largely attributable to enhanced function of CFTR protein arising from the *Phe508del* allele.¹⁴ In a post hoc subgroup analysis of the percentage of predicted FEV₁, the treatment differences between elxacaftor–tezacaftor–ivacaftor and active control were 5.8 percentage points (95% CI, 3.5 to 8.0) for patients with *Phe508del*–gating genotypes and 2.0 percentage points (95% CI, 0.5 to 3.4) for patients with *Phe508del*–residual function genotypes. Relative to patients with *Phe508del*–gating genotypes, smaller changes in lung function in response to CFTR modulation among patients with *Phe508del*–residual function genotypes have been observed previously and probably reflect differences in the progression of lung disease in patients with *Phe508del*–residual function genotypes, who are generally older than those in other genotype groups.⁸ (In the current trial, such patients had a mean age of 40.8 years, as com-

pared with 32.2 years for patients with *Phe508del*–gating genotypes.) Elxacaftor–tezacaftor–ivacaftor treatment also resulted in changes in CFQ-R respiratory domain scores, relative to ivacaftor or tezacaftor–ivacaftor, that exceeded the established minimal clinically important difference (4 points), a finding that shows further abatement of respiratory symptoms in these patients.^{8,10,16,18}

Sweat chloride concentration may differentiate the effectiveness of CFTR modulator regimens at a population level. At baseline, the mean sweat chloride concentration in patients was approximately 60 mmol per liter, the threshold for definitive diagnosis of cystic fibrosis.¹⁹ After 8 weeks of elxacaftor–tezacaftor–ivacaftor treatment, 50.0% of the patients had sweat chloride concentrations below 30 mmol per liter, a level that matches those generally seen in the population of asymptomatic carriers with a single mutant *CFTR* allele and a level below which a diagnosis of cystic fibrosis is unlikely,^{19,20} whereas only 17.6% of the patients who received active control had sweat chloride concentrations below 30 mmol per liter. This result reflects improved CFTR function with elxacaftor–tezacaftor–ivacaftor treatment.

This phase 3 trial showed the efficacy of elxacaftor–tezacaftor–ivacaftor therapy in patients with *Phe508del*–gating and *Phe508del*–residual function genotypes, with clinical benefit exceeding previous CFTR modulators. No new safety findings were noted as compared with previous studies involving patients with cystic fibrosis.^{14,17} Sweat chloride concentrations after elxacaftor–tezacaftor–ivacaftor treatment reached levels at or near those found in asymptomatic carriers with a single *CFTR* mutation. These findings confirm the efficacy and safety of elxacaftor–tezacaftor–ivacaftor in patients with at least one *Phe508del* allele.

Supported by Vertex Pharmaceuticals. The National Institute for Health Research (NIHR) provided support to the NIHR Manchester Clinical Research Facility. The National Institutes of Health provided support to the University of Alabama (P30DK072482 and UL1TR003096) and the University of Kansas Medical Center Research Institute (P20GM130423).

Disclosure forms provided by the authors are available at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank the patients and their families for participating in this trial and all site investigators and coordinators for their contributions to the trial; the members of the Cystic Fibrosis Foundation Therapeutics Development Network and the European Cystic Fibrosis Society Clinical Trials Network for their

support of the trial sites; Emily Poulin, Ph.D., an employee of Vertex Pharmaceuticals, who may own stock or stock options in the company, for providing editorial coordination and support; and Nathan Blow, Ph.D., of Vertex Pharmaceuticals, who may

own stock or stock options in the company, and Christopher Edwards, Ph.D., C.M.P.P., of ArticulateScience, for providing editorial assistance under the guidance of the authors and with support from Vertex Pharmaceuticals.

APPENDIX

The authors' full names and academic degrees are as follows: Peter J. Barry, M.D., Marcus A. Mall, M.D., Antonio Álvarez, M.D., Carla Colombo, M.D., Karin M. de Winter-de Groot, M.D., Isabelle Fajac, M.D., Ph.D., Kimberly A. McBennett, M.D., Ph.D., Edward F. McKone, M.D., Bonnie W. Ramsey, M.D., Sivagurunathan Sutharsan, M.D., Jennifer L. Taylor-Cousar, M.D., M.S.C.S., Elizabeth Tullis, M.D., Neil Ahluwalia, M.D., Lucy S. Jun, Ph.D., Samuel M. Moskowitz, M.D., Valentin Prieto-Centurion, M.D., Simon Tian, M.D., David Waltz, M.D., Fengjuan Xuan, Ph.D., Yaohua Zhang, Ph.D., Steven M. Rowe, M.D., M.S.P.H., and Deepika Polineni, M.D., M.P.H.

The authors' affiliations are as follows: Manchester University NHS Foundation Trust, Manchester, United Kingdom (P.J.B.); Charité-Universitätsmedizin Berlin, the Berlin Institute of Health, and the German Center for Lung Research, Berlin (M.A.M.), and the Division of Cystic Fibrosis, Department of Pulmonary Medicine, University Medicine Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen (S.S.) — all in Germany; Vall d'Hebron Barcelona Hospital Campus, Barcelona (A.A.); Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan — both in Milan (C.C.); Wilhelmina Children's Hospital—University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands (K.M.W.-G.); Assistance Publique-Hôpitaux de Paris (AP-HP) Centre-Université de Paris Hôpital Cochin AP-HP, Paris (I.F.); Rainbow Babies and Children's Hospital, Cleveland (K.A.M.); St. Vincent's University Hospital, Dublin (E.F.M.); Seattle Children's Hospital, Seattle (B.W.R.); National Jewish Health, Denver (J.L.T.-C.); St. Michael's Hospital, Toronto (E.T.); Vertex Pharmaceuticals, Boston (N.A., L.S.J., S.M.M., V.P.-C., S.T., D.W., F.X., Y.Z.); the University of Alabama at Birmingham, Birmingham (S.M.R.); and the University of Kansas Medical Center, Kansas City (D.P.).

REFERENCES

- Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. *Lancet Respir Med* 2020;8:65-124.
- De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. *Lancet Respir Med* 2016;4:662-74.
- Elborn JS. Cystic fibrosis. *Lancet* 2016; 388:2519-31.
- Accurso FJ, Van Goor F, Zha J, et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. *J Cyst Fibros* 2014;13: 139-47.
- Cystic Fibrosis Mutation Database (CFTR1). 2011 (<http://www.genet.sickkids.on.ca/>).
- The Clinical and Functional Translation of CFTR (CFTR2). 2011 (<https://cftr2.org/>).
- Cystic Fibrosis Foundation patient registry: 2018 annual data report. Bethesda, MD: Cystic Fibrosis Foundation, 2019.
- Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. *N Engl J Med* 2017;377:2024-35.
- Van Goor F, Hadida S, Grootenhuus PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. *Proc Natl Acad Sci U S A* 2009;106:18825-30.
- Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 2011;365:1663-72.
- Van Goor F. Nonclinical profile of the CFTR corrector VX-661. Presented at the 30th annual North American Cystic Fibrosis Conference, Orlando, FL, October 27-29, 2016. (Poster.)
- Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. *N Engl J Med* 2017;377:2013-23.
- Keating D, Marigowda G, Burr L, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. *N Engl J Med* 2018;379: 1612-20.
- Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. *N Engl J Med* 2019;381:1809-19.
- Mall MA, Mayer-Hamblett N, Rowe SM. Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications. *Am J Respir Crit Care Med* 2020;201:1193-208.
- De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. *J Cyst Fibros* 2014;13:674-80.
- Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. *Lancet* 2019;394:1940-8.
- Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic *Pseudomonas aeruginosa* airway infection. *Chest* 2009;135:1610-8.
- Farrell PM, White TB, Ren CL, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. *J Pediatr* 2017;181:Suppl:S4-S15.e1.
- Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. *Am J Respir Crit Care Med* 2006;174:787-94.

Copyright © 2021 Massachusetts Medical Society.